The U.S. Food and Drug Administration (FDA) has conditionally approved Keytruda (pembrolizumab) for the treatment of pediatric and adult patients with inoperable or metastatic solid tumors with high tumor mutational burden (TMB-H). This is the second time the FDA approved Merck‘s immune checkpoint inhibitor Keytruda for cancer patients with specific genetic features in their tumors rather than a specific tumor type. Full approval for this indication, which includes patients who have progressed following prior treatment and…
You must be logged in to read/download the full post.
The post Keytruda Approved to Treat Solid Tumors With High Mutational Burden appeared first on BioNewsFeeds.